Abstract: Poster Presentations |

Improved Small Airway Function With Fluticasone Propionate/Salmeterol versus Ipratropium/Albuterol Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) FREE TO VIEW

K Knobil, MD; M Watkins, PharmD; K Merchant, PhD; A Emmett, MS; S Schweiker, BS; J Yates, BS
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest. 2003;124(4_MeetingAbstracts):165S. doi:10.1378/chest.124.4_MeetingAbstracts.165S-b
Text Size: A A A
Published online


PURPOSE:  The patency of small airways is assessed by the forced expiratory flow (FEF25–75%), which is decreased in obstructive airways due to mucus secretion, bronchospasm, inflammation, and alveolar destruction. The purpose of this analysis was to determine the effect of fluticasone propionate 250 mcg/salmeterol 50 mcg therapy (FSC 250/50) compared to ipratropium 36mcg/ albuterol 206mcg (Ipr/Alb) on the small airways in patients with COPD.

METHODS:  In this multicenter, double-blind, double-dummy study, 361 patients with COPD were randomized to FSC 250/50 BID via the Diskus or Ipr/Alb QID via a metered-dose inhaler for 8 weeks. The function of the small airways was investigated by measurement of the FEF25–75% at baseline and at 1, 4 and 8 weeks of therapy. Patients had COPD, an extensive smoking history (mean = 59 pack years) and impaired lung function (mean FEV1 43% of predicted).

RESULTS:  Pre-dose FEF25–75% mL/sec Mean Δ from Baseline (SE)FSC 250/50 (n = 179)Ipr/Alb (n = 181)p-valueWeek 144.5 (13.4)−9.7 (9.5)<0.001Week 443.4 (12.9)−3.7 (12.5)0.007Week 855.0 (16.7)−6.6 (11.7)<0.001Endpoint56.9 (16.0)−6.8 (10.9)<0.001

CONCLUSION:  In patients with COPD, FSC 250/50 caused significant improvements in small airway function within the first week and was sustained with continued therapy.

CLINICAL IMPLICATIONS:  In patients with COPD treatment with FSC250/50 demonstrated improvements in small airway function, suggesting that the prolonged improvements in lung function may be due to the anti-inflammatory effects of the combination.

DISCLOSURE:  K. Knobil, Employee of GSK, Industry; support: GlaxoSmithKline

Wednesday, October 29, 2003

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543